Search Blog
December 2013
« Nov   Jan »


Morning Buzz: Twitter Inc, Anadarko Petroleum Corporation, QUALCOMM, AstraZeneca plc


By PrimeTimeMedia LLC

New York, December 13, 2013 / Accesswire / – Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Twitter Inc(NYSE:TWTR), Anadarko Petroleum Corporation(NYSE:APC), QUALCOMM, Inc.(NASDAQ:QCOM), AstraZeneca plc (ADR)(NYSE:AZN).

“A substantial 40% of Twitter Inc(NYSE:TWTR) advertisers reported improving ROI over the last six months and 40% have also increased their Twitter spend,” says RBC Capital, upping its price target on Buy-rated Twitter to $60 from $33.59% of respondents plan to increase ad spend with Twitter over the next twelve months, says the team, while only 4% plan to decrease. Shares +1.2% premarket to $56.

Free Urgent Insider Catalyst Report For TWTR Available Here: (Or Copy and paste the URL into your browser)

Anadarko Petroleum Corporation(NYSE:APC) almost certainly will appeal yesterday’s court ruling against it in the Tronox litigation: “We vehemently disagree with the judge’s [decision]… We fully expect to pursue every avenue available to us through the appellate process to protect the interests of our stakeholders, once a final judgment including damages has been rendered.”The severity of the ruling for APC will come down to damages: While the judge found that the trust is entitled to recover ~$14.17B, APC may be able to lower the figure by ~$9B for offsetting costs it may have incurred from the Tronox transaction.J.P. Morgan downgrades APC to Underweight and a $77 price target, while Citi and Global Hunter cut shares to Neutral from Buy; Credit Suisse views $65-$70 as a potential floor level valuation.

Free Urgent Insider Catalyst Report For APC Available Here: (Or Copy and paste the URL into your browser)

QUALCOMM, Inc.(NASDAQ:QCOM) moves quickly after rumors COO Steve Mollenkopf was under consideration for the top spot at Microsoft (MSFT), promoting him to CEO and to the board, effective March 4. Paul Jacobs will become Executive Chairman.

Free Urgent Insider Catalyst Report For QCOM Available Here: (Or Copy and paste the URL into your browser)

AstraZeneca plc (ADR)(NYSE:AZN) Lesinurad treatment for gout met the primary goal of a Phase III study, although it caused a number of side effects, some of which were serious.The study tested Lesinurad for use in the small number of patients who are unable to take rival therapies allopurinol and febuxostat.The side effects included increased levels of serum creatinine, which are an important indicator of renal health.AstraZeneca is now waiting for the outcomes of three other Phase III trials, which are testing Lesinurad in combination with other drugs.

Free Urgent Insider Catalyst Report For AZN Available Here: (Or Copy and paste the URL into your browser)  is an investment community that Focuses on MicroCap Securities. is an  authorative authentic Google News Site and  Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit  for more details. Get an edge on the market with our Premium News Alerts   that are FREE for a limited time at

Follow us on Facebook:

Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126.  (SMS alerts are free, however data rates may apply, check your wireless plan for details.)